Appreciate the authors' detailed compilation and analysis of data from several sources across a large number of countries. It would be helpful if (particularly for those among readership who are more clinically focused) to provide a bit more explanation of the calculated thresholds, how those are arrived at, and how these differ from the national thresholds set by each country.

Minor comments:
Line 31 (and line 338): "RSV circulation during the 2022/23 season had not yet normalised." - I am not seeing data for the 2022/23 season - maybe clarify if this refers to the 2022 interseason?
Line 96: "approaching licensure" - is Abrysvo not approved by EMA now?
Line 97: Does this need to be updated to reflect Nirsevimab availability to protect all infants, not just those with heart/lung comorbidities?
Line 116: typo ("presenting toe primary care")
Line 117: typo - closing bracket missing after "previously"?
Line 121: consider including brief description of the moving epidemic method for those not familiar with this
Line 125: how is country-specific epidemic threshold determined?
Line 130: typo - "sixteen in 2021/2022al periods" - not sure what "2022al" is, missing word?
Line 176: I find this wording confusing - "the start of the 2021/22 season was already discernible in the latter part of the 2021 inter-seasonal period with detections peaking before or after week 40/2021" - did they peak before, or after? Or just around that time?